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Parkinson’s disease is a neurodegenerative disorder that can, at least partly, be mimicked by the neurotoxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine. S100B is a calcium-binding protein expressed in, and secreted by, astrocytes. There is
increasing evidence that S100B acts as a cytokine or damage-associated molecular pattern protein not only in inflammatory
but also in neurodegenerative diseases. In this study, we show that S100B protein levels were higher in post-mortem substantia
nigra of patients with Parkinson’s disease compared with control tissue, and cerebrospinal fluid S100B levels were higher in a
large cohort of patients with Parkinson’s disease compared with controls. Correspondingly, mice treated with
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine showed upregulated S100B messenger RNA and protein levels. In turn, ablation
of S100B resulted in neuroprotection, reduced microgliosis and reduced expression of both the receptor for advanced glycation
endproducts and tumour necrosis factor-a. Our results demonstrate a role of S100B in the pathophysiology of Parkinson’s
disease. Targeting S100B may emerge as a potential treatment strategy in this disorder.
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Abbreviations: COX = cyclooxygenase; MPP + = 1-methyl-4-phenylpyridinium;
MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; RAGE = receptor for advanced glycation endproducts; TNF = tumour
necrosis factor
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Introduction
Parkinson’s disease is a common progressive neurodegenerative
disorder characterized by the accumulation of aggregated
-synuclein in neurons of particular brain regions, including the
brainstem and cortical regions, and by severe loss of dopaminergic
neurons (Lees et al., 2009). There is increasing evidence that glial
cells are crucially involved in the initiation and progression of the
disease (Halliday and Stevens, 2011). For example, astrocytes have
recently been shown to effectively endocytose -synuclein pro-
teins secreted from neurons, and to produce glial inclusions and
inflammatory responses (Lee et al., 2011). The distribution of
-synuclein-positive astrocytes parallels the distribution of Lewy
bodies (Braak et al., 2007). In addition, animal models suggest
that microglia are involved early in Parkinson’s disease (Halliday
and Stevens, 2011). In turn, specific inhibition of microglial cells
led to a significant attenuation of the Parkinson’s disease-like dis-
ease process caused by the neurotoxin 1-methyl-4-phenyl-1,
2,3,6-tetrahydropyridine (MPTP) (Wu et al., 2002). MPTP is a
neurotoxin that causes Parkinson’s disease in humans and pri-
mates, which is clinically almost indistinguishable from sporadic
Parkinson’s disease (Langston and Irwin, 1986).
S100B, a calcium-binding protein, is synthesized in, and consti-
tutively secreted by, astrocytes (Van Eldik and Zimmer, 1987; Sorci
et al., 2010). S100B levels are positively associated with age, and
increased S100B concentrations have been detected in various
neurodegenerative and neuroinflammatory diseases (Rothermundt
et al., 2003; Sorci et al., 2010). An increase of S100B-positive
astroglia 1 day after MPTP administration (Muramatsu et al.,
2003) gives rise to the hypothesis that this protein may also be
involved in Parkinson’s disease pathogenesis. This finding, how-
ever, cannot rule out the alternative hypothesis that the increase
in S100B might merely present an unspecific secondary effect,
without playing a causal role in Parkinson’s disease-related neuro-
degeneration. Indirect evidence for an involvement of S100B in
dopaminergic dysfunction comes from genetic studies. An associ-
ation of the single-nucleotide polymorphism rs3788266 of the
S100B gene with schizophrenia and psychosis in bipolar affective
disorders was recently reported (Liu et al., 2005; Roche et al.,
2007).
Most interestingly, S100B at low (nanomolar) concentrations
acts as a neurotrophic factor promoting neuronal survival and
neurite growth during development and under stress (Bianchi
et al., 2007). Yet, at high (micromolar) concentrations, S100B
causes neuronal apoptosis both by direct action on neurons and
activation of microglia (Hu et al., 1997; Li et al., 2000; Sorci et al.,
2010). These effects may, to some extent, be mediated by acti-
vation of inducible nitric oxide synthase (an enzyme responsible
for the production of nitric oxide), and by inducing elevated levels
of intracellular calcium and caspase-3 activation (Hu et al., 1997;
Iuvone et al., 2007). Another mechanism includes the receptor for
advanced glycation endproducts (RAGE) pathways (Kerkhoff
et al., 1998; Donato, 1999; Hofmann et al., 1999; Bianchi
et al., 2011; Villarreal et al., 2011). RAGE is a member of the
immunoglobulin superfamily and can be bound by several ligands,
including S100B. Both the pro-survival (at low concentrations) and
the toxic effect (at high concentrations) of S100B appear, at least
partly, to be because of RAGE-mediated nuclear factor-B activa-
tion (Huttunen et al., 2000; Villarreal et al., 2011). S100B can also
upregulate neuronal RAGE expression (Kogel et al., 2004;
Businaro et al., 2006; Villarreal et al., 2011). Based on these find-
ings and the hypothesis that S100B is involved in Parkinson’s dis-
ease pathogenesis, we set out to study S100B levels in patients
with Parkinson’s disease and MPTP-treated mice, and to explore
the consequences of S100B in S100B/ mice. Here, we report
that S100B is upregulated in the substantia nigra and CSF of pa-
tients with Parkinson’s disease, as well as in MPTP-treated mice.
Reduced gliosis and decreased expression and activation of both
RAGE and the pro-inflammatory cytokine tumour necrosis factor
(TNF)- in S100B/ mice treated with MPTP indicate that abla-
tion of S100B is neuroprotective in Parkinson’s disease-like
processes.
Materials and methods
Human samples
Six post-mortem human midbrain samples (frozen tissue samples and
prepared slices) from patients with Parkinson’s disease and five control
samples matched for age at death and interval from death to tissue
processing (see Supplementary material) were obtained from the
Parkinson’s UK Brain Bank at Imperial College, London, UK. Human
serum, CSF and DNA samples of 82 patients with Parkinson’s disease
and 64 controls were collected under fasting conditions between 8.00
and 10.00 a.m. at the ward and outpatient clinic of the
Neurodegenerative Department of the University of Tu¨bingen accord-
ing to the highest international standards on biobanking. For details
see Maetzler et al. (2011a). Demographics and clinical data are shown
in Table 1.
Determination of S100B levels in
cerebrospinal fluid and serum,
and genotyping
S100B protein levels were measured blinded to the subject’s state (i.e.
patient or control) using an automated immunoassay (LIAISON,
DiaSorin). The assay is based on a non-competitive ligand-binding
method (sandwich principle). Genotyping of single-nucleotide poly-
morphism rs3788266 of the S100B gene was performed as described
elsewhere (Maetzler et al., 2011b).
Animals and treatment
Wild-type C56/BL7 mice were obtained from Charles River
Laboratories. S100B/ mice were obtained from the Shigeyoshi
Itohara Laboratory, Behavioural Genetics, Brain Science Institute,
RIKEN, Japan, and genotyping was performed as published previously
(Nishiyama et al., 2002). Animals received five injections of 30 mg/kg
MPTP intraperitoneally for 5 consecutive days and were sacrificed at
selected time points after the last injection (0, 2, 4, 7, 14 and 21 days).
This protocol was in accordance with the Home Office regulations.
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RNA extraction and reverse transcription
polymerase chain reaction
Total RNA was extracted from selected mouse brain regions as
described earlier (Teismann et al., 2003). Complementary DNA was
amplified using the Roche LightCycler 480. The primer mouse se-
quences used were as follows: RAGE, 50-CAGCATCAG
GGTCACAGAAA-30 (forward) and 50-CTGGTTGGAGAAGGAAG
TGC-30 (reverse); S100B, 50-GCTGACCACCATGCCCCTGTAG-30 (for-
ward) and 50-CTGGCCATTCCCTCCTCTGTC-30 (reverse). As internal
control, b-actin complementary DNA was co-amplified using the
primer sequences 50-TGTGATGGTGGAATGGGTCAG-30 (forward) and
50-TTTGATGTCACGCACGATTTCC-30 (reverse).
Immunoblots
Mouse and human brain extracts were prepared and western blot
analyses performed as described previously (Teismann et al., 2003).
Primary antibodies were as follows: S100B (1:1000, monoclonal,
Sigma), RAGE (1:1000, Sigma), cyclooxygenase (COX)-2 (1:250, BD
Bioscience), inducible nitric oxide synthase (1:500, BD Bioscience),
TNF- (1:1000, Abcam), b-actin (1:25 000, Sigma), ionized calcium-
binding adaptor molecule 1 (1:2000, Wako Chemicals, Neuss) and glial
fibrillary acid protein (GFAP; 1:1000, DAKO). Horseradish
peroxidise-conjugated secondary antibodies (anti-rabbit or anti-mouse
1:10000, Amersham) and enhanced chemiluminescence solution
(Luminol sodium salt in 0.1 mM Tris HCl and para-hydroxycoumarin
in dimethyl sulphoxide) were used for chemiluminescence detection.
Bands were quantified using the FluorChem 8800 digital image system
(Alpha Innotech).
S100B immunohistochemistry
All immunohistochemistry analyses were performed according to
our standard protocols for immunostaining (Teismann et al.,
2003). Primary antibodies (in phosphate buffered saline (PBS)–
Triton–normal goat serum) were as follows: S100B (1:1000, monoclo-
nal, Sigma Aldrich), GFAP (1:1000, DAKO), tyrosine hydroxylase (TH,
1:1000, Millipore UK) and ionized calcium-binding adaptor molecule 1
(1:500, Wako Chemicals, Neuss). The sections were incubated in
anti-rabbit (1:200, Cy3, Jackson ImmunoResearch) or anti-mouse
(1:300, AlexaFluor 480, Molecular Probes) fluorescing antibodies
for visualization using confocal microscopy. Tyrosine hydroxylase
immunohistochemistry was carried out as described previously
(Teismann et al., 2003), and the sections were counterstained with
Nissl. The tyrosine hydroxylase- and Nissl-positive substantia nigra
pars compacta neurons were counted using the optical fractionators
method with the examiner being blinded to genotype and treatment.
Striatal density of tyrosine hydroxylase immunoreactivity was mea-
sured as described elsewhere (Teismann et al., 2003).
High-performance liquid
chromatography
Levels of dopamine and its metabolites, 3,4-dihydroxyphenylacetic
acid and homovanillic acid, were measured in striatal samples
(Teismann et al., 2003).
Immunocytochemistry
SH-SY5Y cells were grown on coverslips in 24-well plates and plated at
a density of 40 000 cells/well. After 48 h, the medium was replaced
with serum-free Dulbecco’s modiEed Eagle’s medium and RAGE anti-
body, at a concentration of 25mg/ml, or PBS was added. S100B anti-
body was added 24 h later at a concentration of 10mg/ml.
1-Methyl-4-phenylpyridinium (MPP + ) was also added at this stage,
to give a final concentration of 1.5 mM. After further 48 h, cells
were fixed in 4% paraformaldehyde for 15 min. Cells were extensively
washed with PBS between each step. Cells were permeabilized for
10 min in PBS containing 0.1% TritonX (PBS-T). Unspecific binding
was blocked with 10% normal goat serum (Vector Laboratories) in
PBS-T containing 0.3 M glycine. Cells were first incubated in primary
antibodies [mouse tyrosine hydroxylase (1:200; Millipore), rabbit TNF-
 (1:200; Abcam) and rabbit COX-2 (1:500; Abcam)] overnight at 4C
before incubation in 1% normal goat serum in PBS-T with secondary
antibodies [goat anti-mouse Cy3 (1:200; Jackson ImmunoResearch)
and goat anti-rabbit AlexaFluor 488 (1:300; Molecular Probes)] for
1 h at room temperature. The coverslips were mounted, sealed and
imaged by fluorescent microscopy at the same setting.
Statistical analysis
All values are expressed as means  SEM unless stated otherwise.
Differences between means were analysed using Student’s t-test
(two groups) or the one-way ANOVA (more than two groups).
When ANOVA showed significant differences, pair-wise comparisons
between means were assessed using the Newman–Keuls post hoc test.
Pearson correlation coefficient was used for correlation analyses, and
the Pearson’s chi-square test for comparison of categorical data
(42  2 table). Concerning CSF results, a receiver-operating charac-
teristic curve was used to calculate the relationship between sensitivity
and specificity for Parkinson’s disease versus healthy controls. Null
Table 1 Demographic and clinical data, including serum and CSF S100B levels, of subjects with Parkinson’s disease and
control subjects
Demographic and clinical features Parkinson’s disease Controls P-value
Subjects (female) 82 (42) 64 (41) 0.18
Age at examination (years), mean (SD) 69 (8) 67 (9) 0.11
Age at onset of parkinsonism (years), mean (SD) 61 (9)
Disease duration (years), mean (SD) 8 (6)
Hoehn and Yahr stage median (range) 2 (1–4)
CSF S100B (mg/l), mean (SD) 3.1 (1.0) 2.2 (1.1) 50.0001
Serum S100B (mg/l), mean (SD) 0.09 (0.06) 0.08 (0.04) 0.18
Hoehn and Yahr staging was performed in an OFF medication state.
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hypothesis was rejected at a 0.05 level. All analyses were performed
using SPSS for Windows software.
Results
S100B is upregulated in substantia nigra
of patients with Parkinson’s disease
Immunostaining for S100B and RAGE protein in post-mortem
midbrain slices of Parkinson’s disease and control subjects revealed
significantly higher S100B protein levels in Parkinson’s disease
(Fig. 1A). S100B was mainly localized in GFAP-positive astrocytes
(Fig. 1C–E and L). We found S100B-positive structures neither in
tyrosine hydroxylase-positive/Nissl-stained neurons (Fig. 1F–H)
nor in microglia (Fig. 1I–K). RAGE protein levels were not signifi-
cantly different between Parkinson’s disease and control cases
(Fig. 1B).
S100B levels are increased in
cerebrospinal fluid of patients with
Parkinson’s disease
Measurement of S100B CSF and serum levels revealed that in CSF
S100B levels were higher in patients with Parkinson’s disease com-
pared with controls (3.10 versus 2.20 mg/l; P50.0001; Table 1
and Fig. 2A). The area under the receiver operating characteristic
curve as a measure for the discrimination between Parkinson’s
disease and controls equalled 0.76 (Fig. 2B), indicating a moderate
discriminative effect. CSF S100B levels tended to be higher with
higher age (0.02 mg/l/year; P = 0.08; Fig. 2C). Serum S100B levels
were not significantly different between patients with Parkinson’s
disease and controls (Fig. 2D). CSF and serum S100B levels were
neither associated with age at disease onset nor with Hoehn and
Yahr scores (a measure of disease stage). Gender was neither
associated with CSF (P = 0.67) nor with serum S100B levels
(P = 0.14). Genotype analysis of single-nucleotide polymorphism
rs3788266 showed neither an association with CSF (P = 0.59) or
serum S100B levels (P = 0.71), nor with occurrence of Parkinson’s
disease diagnosis (P = 0.73).
S100B and RAGE RNA and protein
levels are increased in the ventral
midbrain area containing the
substantia nigra pars compacta of
MPTP-treated mice
Analysis of messenger RNA and protein expression of S100B and
RAGE in the ventral midbrain (the brain region that contains the
substantia nigra pars compacta) demonstrated that S100B messen-
ger RNA and protein levels increased immediately after MPTP ad-
ministration and then returned gradually back to baseline levels
(Fig. 3A and C). S100B messenger RNA and protein levels were
increased at Day 0 after MPTP administration and RAGE messen-
ger RNA and protein levels at Day 2 after MPTP administration.
This indicates that induction of RAGE expression occurs later than
S100B expression (Fig. 3B and D). During the following days,
S100B and RAGE messenger RNA levels dropped below baseline
levels, and protein levels returned to baseline levels.
Immunohistochemistry revealed that S100B was mainly localized
in astrocytes (Fig. 3E–G, 3D image in Fig. 3N), confirming
previously published results (Van Eldik and Zimmer, 1987; Sorci
et al., 2010). S100B was rarely found in microglia in our studies
(Fig. 3K–M) and was absent in tyrosine hydroxylase-positive neu-
rons (Fig. 3H–J).
Toxicity of MPTP is reduced in
S100B-ablated mice
Using stereology, significantly more tyrosine hydroxylase-positive
(54.4%) and Nissl-stained (89.7%) neurons survived in S100B/
than in S100B + / + mice after MPTP treatment (42.0% and 59.5%,
respectively, P5 0.001; Fig. 4B and Supplementary Table 1).
Correspondingly, the density of tyrosine hydroxylase-positive
fibres in the striatum was decreased to 36% in S100B/
MPTP-treated mice (compared with saline-treated mice), but to
14% in S100B + / + MPTP-treated mice (Supplementary Table 1).
Numbers of tyrosine hydroxylase-positive neurons and Nissl-
stained cells were comparable between saline-treated S100B/
and S100B + / + mice (Fig. 4B and Supplementary Table 1).
To assess whether ablation of S100B influences striatal dopa-
minergic dysfunction after MPTP treatment, we determined levels
of dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic
acid in the striata of S100B + / + and S100B/ mice after MPTP
administration using high-performance liquid chromatography.
Loss of striatal dopamine was significantly less pronounced in
MPTP-treated S100B/ mice when compared with MPTP-
treated S100B + / + mice (Fig. 4C and Supplementary Table 2).
No impairment of MPTP metabolism
due to ablation of S100B
The main factor in MPTP-induced toxicity is its conversion to
MPP + . Measurement of striatal MPP + levels in S100B + / + and
S100B/ mice, however, revealed comparable results (Supple-
mentary Table 3).
MPTP toxicity is S100B mediated via
RAGE and tumour necrosis factor-a in
the mouse midbrain
Assessment of the influence of S100B ablation on MPTP-induced
effects revealed significantly lower RAGE protein levels in the mid-
brain of S100B/ mice compared with S100B + / + mice after
MPTP administration (Fig. 5A). Comparable results were obtained
for TNF- (Fig. 5D), with TNF- levels being lower in S100B/
mice than in S100B + / + mice after MPTP administration. COX-2
and inducible nitric oxide synthase protein levels were not signifi-
cantly different between the mouse strains after MPTP adminis-
tration (Fig. 5B and C).
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Tumour necrosis factor-a is induced via
RAGE in SH-SY5Y cells
Treatment of SH-SY5Y cells with S100B and/or MPP + led to
increased staining intensity of COX-2 (Fig. 6C, E and G) and
TNF- (Fig. 6D, F and H) as visualized by confocal microscopy.
Addition of RAGE neutralizing antibody (Fig. 6I and K) led to an
attenuation of this intensity.
MPTP toxicity is S100B mediated via
microgliosis
As S100B response is linked to inflammation, we assessed whether
the protective effect of S100B ablation is associated with a reduc-
tion of MPTP-induced glial response. Mouse ventral midbrain area
containing the substantia nigra pars compacta of S100B + / + and
S100B/ mice after MPTP treatment was either prepared for
western blotting or for immunostaining. They were stained for
ionized calcium-binding adaptor molecule 1, a specific marker
for microglial cells, and GFAP, a specific marker for astrocytes
(Fig. 7C). When using western blot, ionized calcium-binding adap-
tor molecule 1 levels in the ventral midbrain containing the sub-
stantia nigra pars compacta were significantly higher in S100B + / +
than in S100B/ mice (Fig. 7A). Similarly, stereological counting
revealed a significantly higher number of ionized calcium-binding
adaptor molecule 1-positive cells in the substantia nigra pars
compacta of S100B + / + mice than in the substantia nigra pars
compacta of S100B/ mice (Fig. 7D). Although astroglial cell
count increased in both strains 3 weeks after MPTP treatment,
GFAP protein levels and numbers of GFAP-positive cells did not
differ between S100B + / + and S100B/ mice (Fig. 7B and D).
Discussion
Elevated S100B level has been shown to be involved in neurotoxic
pathways (Mrak et al., 1996; Rothermundt et al., 2003).
Therefore, it is tempting to speculate that elevated S100B levels
might be related to Parkinson’s disease-associated disease
Figure 1 S100B and RAGE protein in the substantia nigra of patients with Parkinson’s disease. Using western blotting, substantia nigra
S100B protein levels are, as a mean, higher in six samples of Parkinson’s disease (PD), compared with five control samples (A), whereas
RAGE protein levels are comparable (B). Double immunofluorescence studies reveal that S100B (green) co-localizes with GFAP, an
astrocytic marker (red; C–E and a 3D inset, L). S100B is not abundantly expressed in tyrosine hydroxylase neurons (red; F–H) but can be
found in single calcium-binding adaptor molecule 1 (Iba1)-positive cells (red; I–K).
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processes. This hypothesis is corroborated by recent results indi-
cating that astrocytes—the main source of S100B—are fundamen-
tally involved in the pathophysiology of Parkinson’s disease.
Astrocytes can endocytose -synuclein proteins secreted from
neurons, can often have -synuclein-positive inclusions in regions
where Lewy bodies occur and, as a consequence of this process,
can initiate inflammatory responses (Braak et al., 2007; Lee et al.,
2011). Although there is no direct evidence for an interaction of
amyloidogenic pathways and increased S100B expression in
Parkinson’s disease, it is suggestive that such mechanisms lead
to a vicious cycle with, hypothetically, increased intracellular
nitric oxide and calcium burden, as well as apoptosis (Hu et al.,
1997; Iuvone et al., 2007).
In this study, we detected increased S100B protein levels in the
substantia nigra of patients with Parkinson’s disease, as well as in
the ventral midbrain containing the substantia nigra pars compacta
of MPTP-treated mice, a model for Parkinson’s disease. Elevated
S100B messenger RNA levels were also seen in the same region,
suggesting that increased expression of S100B may contribute to
Parkinson’s disease pathogenesis. These changes occurred imme-
diately after treatment with MPTP, suggesting that S100B upre-
gulation could be the trigger for activation of other downstream
molecules involved in the pathogenesis of Parkinson’s disease.
Over time, protein levels returned to baseline, and messenger
RNA levels even dropped below baseline. This indicates that
these organisms are able to counteract the initial reaction simply
by downregulation of the expression pathways. This can lead,
despite increasing numbers of astrocytes at the lesion site, to rela-
tively stable S100B levels that are close to baseline. In Parkinson’s
disease, these regulatory mechanisms seem to be corrupted. This is
corroborated by increased S100B protein levels in the substantia
nigra and in the CSF of patients with Parkinson’s disease, com-
pared with controls. How these regulation mechanisms are af-
fected is a matter of further research.
The MPTP model leads to rapid and immediate cell death
compared with cell death in human Parkinson’s disease, even
when a relatively ‘subacute’ regimen of MPTP application is
chosen (5  30 mg/kg intraperitoneally) (Tatton and Kish,
Figure 2 S100B levels in CSF and serum of patients with Parkinson’s disease. In the immunoassay, significantly higher S100B levels are
detectable in CSF of 84 patients with Parkinson’s disease (PD) compared with 62 neurodegeneratively healthy subjects (HC) (A). The area
under the curve (AUC) equals 0.76, indicating a moderate accuracy of the parameter in differentiating the groups (B). CSF S100B levels of
patients with Parkinson’s disease and healthy subjects tend to be higher with higher age (C). In serum, S100B levels do not significantly
differentiate between Parkinson’s disease and healthy subjects (D). Note also the substantially lower S100B levels in serum compared with
CSF (A and D).
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1997). Therefore, extrapolation of data from the MPTP model to
human Parkinson’s disease requires particular caution.
Nevertheless, this model is useful for indicating processes that
might be involved in the pathogenesis and potential treatment
strategies that, as in this study, need to be evaluated in the
human disease condition (Langston et al., 1983; Langston and
Irwin, 1986).
In the brain, trophic and toxic effects of extracellular S100B are
mediated by RAGE (Hofmann et al., 1999). RAGE, a 45-kDa cell
surface multi-ligand receptor, is found on neurons and microglial
cells (Adami et al., 2004; Bianchi et al., 2011; Villarreal et al.,
2011) and is involved in pro-inflammatory responses by activation
of nuclear factor-B (Yan et al., 1994; Villarreal et al., 2011),
including the expression of interleukin 6 and TNF- (Basta
et al., 2002). In the current study, genetic ablation of S100B
reduced levels not only of RAGE but also of TNF-, as shown
by western blotting. An increase in levels of the pro-inflammatory
cytokine TNF- is seen as a reaction to cell death as part of the
inflammatory cascade. RAGE has been correlated to enhanced re-
lease of TNF- and nuclear factor-B and the activation of the
Janus kinase-signal transducer and activator of transcription
(STAT) pathway (Sriram et al., 2004). Furthermore, RAGE
Figure 3 S100B and RAGE messenger RNA and protein in mouse ventral midbrain area containing the substantia nigra after MPTP. In
mice, real-time polymerase chain reaction and western blot tests indicate that S100B messenger RNA and protein levels are increased
directly at Day 0 after MPTP treatment. Within 3 weeks, S100B protein levels returned back to base levels, whereas messenger RNA levels
dropped even below base levels (A and C). RAGE protein levels are increased 2 days after MPTP treatment and then drop back to base
levels, whereas RAGE messenger RNA levels drop below base levels (B and D). Double immunofluorescence reveals that S100B protein
(green) co-localizes with GFAP, an astrocytic marker (red; E–G and an enlarged 3D inset, N). S100B is not detectable in tyrosine
hydroxylase neurons (red; H–J) but can be found in single ionized calcium-binding adaptor molecule 1 (Iba1)-positive cells (red; K–M).
Data are mean  SEM for four to six mice per group. *P50.05 compared with saline (Newman–Keuls post hoc test).
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activation or the Janus kinase-2/STAT3 pathway, which can be
activated through RAGE, is followed by an increased expression
of COX-2 and inducible nitric oxide synthase (Neumann et al.,
1999; Huang et al., 2001). These hypotheses for the action of
RAGE are strengthened by our findings that both RAGE and
S100B messenger RNA are increased in the MPTP mouse model
of Parkinson’s disease. As we did not detect a relevant difference
of COX-2 and inducible nitric oxide synthase protein levels after
MPTP treatment in S100B/ compared with S100B + / + mice, we
suggest that S100B-associated neurodegeneration is primarily
Figure 5 S100B-mediated MPTP toxicity via RAGE and TNF- in the mouse midbrain area containing the substantia nigra pars compacta.
In the immunoblot, ventral midbrain area containing the substantia nigra pars compacta MPTP-induced RAGE (A) and TNF- protein
levels (D) are lower in S100B/ (knockout, KO) mice compared with S100B + / + (wild-type, WT) mice. In contrast, protein levels of
COX-2 (B) and inducible nitric oxide synthase (iNOS) (C) are comparable. Data are mean  SEM for four to six mice per group.
*P5 0.001 compared with MPTP-treated S100B + / + mice (Newman–Keuls post hoc test).
Figure 4 Genetic ablation of S100B rescues dopaminergic neurons from MPTP toxicity. Three weeks after saline treatment, numbers of
tyrosine hydroxylase-positive neurons in the substantia nigra pars compacta are comparable between S100B/ (knockout) and S100B + / +
(wild-type) mice when assessed with stereology (A, upper panels and B; Supplementary Table 1). However, S100B/ mice show higher
numbers of tyrosine hydroxylase-positive neurons in the substantia nigra pars compacta than do S100B + / + mice, indicating a lowered
vulnerability of the S100B/ strain to MPTP (A, lower panels and B; Supplementary Table 1). Accordingly, striatal dopamine depletion as
assessed with high-performance liquid chromatography 3 weeks after MPTP is less severe in S100B/ mice than in S100B + / + mice (C and
Supplementary Table 2). Data are mean  SEM for six mice per group. *P50.001 compared with MPTP-treated S100B + / + mice
(Newman–Keuls post hoc test).
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mediated by the RAGE/TNF- pathway. It is likely that COX-2
and inducible nitric oxide synthase are too far downstream in
the S100B-mediated pathway, and thus, we were not able to
detect any significant changes when using western blotting as a
relatively crude quantification method. Our immunocytochemistry
experiments (Fig. 6) make it indeed tempting to speculate that not
only TNF- but also COX-2 is, through the RAGE pathway,
involved in central S100B action. COX-2 and inducible nitric
oxide synthase are markers of neuroinflammation and oxidative
stress, respectively. COX-2 activation has been shown to be
involved in Parkinson’s disease neurodegeneration (Knott et al.,
2000), and its activation leads to an increase of reactive oxygen
species and to a release of pro-inflammatory cytokines such as
TNF- and interleukin 1 (Teismann et al., 2003). S100B has
been shown to upregulate the expression of COX-2 in microglia
via the Cdc42/Rac1–JNK and a Ras–Rac1–nuclear factor-B path-
way. This requires its binding to RAGE (Bianchi et al., 2007).
Ablation of RAGE also led to a neuroprotective effect associated
with reduced activation of nuclear factor-B in the MPTP model of
Parkinson’s disease (Teismann et al., 2012), indicating a causative
influence of RAGE in this model.
We found a significant neuroprotective effect that, however, did
not lead to a complete protection of nigral dopaminergic neurons.
Two hypotheses of incomplete protection by S100B ablation can
be considered. First, S100B ablation yielded only incomplete pro-
tection, as it did not lead to an attenuation of COX-2 and indu-
cible nitric oxide synthase in vivo, both of which have been shown
to be contributors to cell death in the MPTP model (Liberatore
et al., 1999; Teismann et al., 2003). As these pathways still seem
to be active, they may contribute to the cell degeneration, and
thus, only a partial protection could be achieved. Second, it has
been reported that low levels of S100B exert neuroprotective ef-
fects, thus promoting neuronal survival (Bianchi et al., 2007).
Consequently, the beneficial and deleterious effects of S100B
may have been ablated in a total knockout model. It would be
interesting to see whether S100B knockdown leads to an
enhanced cell survival.
The effect of S100B on Parkinson’s disease-related neurodegen-
eration may also be indirectly mediated. Our data indicate that
genetic ablation of S100B reduces microglial response, strengthen-
ing the hypothesis that S100B activation is involved in the neu-
roinflammation seen in Parkinson’s disease. This could theoretically
also be explained by a reduced requirement for microglia to
remove cell debris after neuronal loss, which was less severe
in S100B/ mice (46% in S100B/ mice versus 58% in
S100B + / + mice, see ‘Results’ section). However, we argue that
Figure 6 TNF- is induced via RAGE in SH-SY5Y cells. COX-2 (A) and TNF- (B) immunocytochemistry in non-stimulated SH-SY5Y cells
shows only faint staining, indicating low cytosolic levels of these proteins under resting conditions. Incubation with MPP + leads to an
intense COX-2 (C) and TNF- (D) staining of the cytoplasm. Incubation with S100B leads to even more intense staining against COX-2 (E)
and TNF- (F). Co-incubation of S100B and a neutralizing RAGE antibody result in reduced COX-2 (I) and TNF- (K) staining intensity
(scale bars = 20 mm).
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the relatively small difference in neuronal loss between the strains
cannot explain the relatively large difference in microgliosis
observed in these strains (6.7% versus 45.5% increase of micro-
glial cells after MPTP treatment; Fig. 7).
We detected higher CSF S100B levels in patients with
Parkinson’s disease compared with controls, reaching an area
under the curve of 0.76 in discriminating these two cohorts. This
makes the protein a putative marker candidate that could be
included in a Parkinson’s disease biomarker array. The facts that
(i) S100B levels are about 20-fold higher in the CSF than in the
serum and (ii) S100B exerts neurotoxic effects when increasing
beyond a certain threshold (Hu et al., 1997; Li et al., 2000;
Bianchi et al., 2007) underline the relevance of the findings
from the human post-mortem and animal experiments presented
here. However, it should be noted that a large proportion of pa-
tients with Parkinson’s disease had relatively low control-like CSF
S100B levels and, vice versa, some controls had high CSF S100B
levels (Fig. 2A). This may, at least partly, be explained by the fact
that Parkinson’s disease, as a phenotype, consists of a (yet un-
defined) number of endophenotypes. Only some may develop
clinical symptoms because of brain inflammation in general, and
S100B dysregulation in particular.
Elevated CSF S100B levels have also been described in several
short- and long-term brain pathologies, e.g. in Alzheimer’s disease
(Petzold et al., 2003), frontotemporal lobar degeneration (Petzold
et al., 2003), schizophrenia (Steiner et al., 2006), short-term brain
injury (Kleindienst et al., 2010) and inflammatory diseases (e.g.
Petzold et al., 2009). Interestingly, one study described elevated
CSF S100B levels only in early stages of Alzheimer’s disease (but
not in later stages). This led the authors to suggest that S100B
plays a role in the initiation and/or facilitation of plaque formation
(Peskind et al., 2001). Another study did not find significant dif-
ferences of CSF S100B levels between patients with Alzheimer’s
disease or dementia with Lewy bodies and controls (Mollenhauer
et al., 2005).
If these CSF studies, the results by Mokuno et al. (1983) and
our results are taken together, it seems plausible that patients with
Parkinson’s disease tend to have higher CSF S100B levels com-
pared with patients with amyloid b pathology, underscoring the
relevance of S100B in this disease entity.
Serum S100B levels were not significantly different between
patients with Parkinson’s disease and controls. This is in line
with a recent publication showing comparable S100B levels be-
tween 40 patients with Parkinson’s disease and controls (Schaf
Figure 7 Microglial and astrocytic markers in the ventral midbrain area containing the substantia nigra pars compacta after MPTP. In
western blot, ionized calcium-binding adaptor molecule 1 (Iba1) levels in the ventral midbrain area containing the substantia nigra pars
compacta of S100B + / + [wild-type (WT)] mice are significantly increased 2 days after MPTP treatment (A and D), whereas they remain
fairly unchanged in S100B/ mice. Immunostaining reveals microgliosis in S100B + / + mice, whereas there is no significant infiltration of
microglia in S100B/ [knockout (KO)] mice (C and D). Markers and counts of astrocytes show no differences between S100B + / + and
S100B/ mice (D). Data are mean  SEM for four to six mice per group. *P5 0.001 compared with MPTP-treated S100B + / + mice
(Newman–Keuls post hoc test).
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et al., 2005). Therefore, serum S100B does not seem to be helpful
as a diagnostic blood marker in Parkinson’s disease.
We found neither an association of single-nucleotide poly-
morphism rs3788266 with Parkinson’s disease occurrence nor
with S100B levels. The polymorphism rs3788266 is, to our know-
ledge, the only known single-nucleotide polymorphism that clearly
influences S100B levels and is associated with dopaminergic dys-
function (Liu et al., 2005; Roche et al., 2007). Our results argue
against a crucial involvement of rs3788266 in the aetiology of
Parkinson’s disease. However, the genetic results found in our
assessed population must be interpreted with caution because of
sample size and need confirmation in larger cohorts. Interestingly,
in the model of MPTP where the neurodegenerative insult occurs
rapidly and only once (in contrast to the neurodegenerative pro-
cess underlying human Parkinson’s disease), both S100B and
RAGE messenger RNA levels initially increased before falling
below baseline while protein levels returned to baseline. This sug-
gests that in predominantly healthy organisms such as the mice
used here, there seems to be a form of counter regulation of the
S100B–RAGE pathway to keep the system stable.
External factors (e.g. newly attracted astrocytes that further in-
crease local S100B levels) may also influence maintenance of the
underlying inflammatory reaction contributing to neurodegenera-
tion. These latter mechanisms seem of particular interest for
Parkinson’s disease pathophysiology in the light of the results pre-
sented here and the finding of Bierhaus et al. (2001), who showed
that the RAGE-dependent activation of nuclear factor-B may
contrast with nuclear factor-B activation mediated by pro-
inFammatory cytokines by being a non–self-limiting process.
In conclusion, the picture emerging from our studies advocates
a causative role of S100B in the pathogenesis of Parkinson’s dis-
ease. The results particularly indicate that binding of S100B to
RAGE may lead to neurodegeneration and the activation of the
inflammatory cascade, thus potentially contributing to the ampli-
fication of inflammation in Parkinson’s disease. The present study
also suggests that S100B might be a viable target to generate new
compounds aimed at slowing the progression of the disease.
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